Now Available: Medtech Insight’s Top 100 Ranking Of Companies By Sales And 2021 Outlook
The leading publicly-owned global cardiology, orthopedic, IVD and imaging companies listed alongside the global top 100
After a year like no other for the global medtech industry, 2021 will present a different set of market challenges for device and diagnostic companies.
You may also be interested in...
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.